Answers are grounded in this paper and cite their sources.
Clinical trial reports improved quality of life in patients with short bowel syndrome, suggesting glepaglutide benefits over placebo.
During exit interviews, patients receiving glepaglutide reported improvements in well-being across multiple domains, noting meaningful reductions in PS volume and a reduced impact of SBS-IF on daily life, which was proportionally greater than in those receiving placebo. These findings underscore the patient-reported positive experiences of glepaglutide and its beneficial effects.
No takes yet. Share an insight, caveat, or question.
Mercer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: